Compare Heron Therapeutics Inc (HRTX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Smith & Nephew plc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 163.2× Heron Therapeutics Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Smith & Nephew plc for 121 Days on average.
| HRTX | SNN | |
|---|---|---|
Market Cap | $68.01M | $11.10B |
Volume | 1,891,941 | 1,051,703 |
Sector | Health | Health |
52-Week High | $1.49 | $37.17 |
52-Week Low | $0.27 | $26.42 |
Typical Hold Time | 35 Days | 121 Days |
Enterprise Value | $174.75M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
